Allergy Therapeutics plc (LON:AGY – Get Free Report)’s stock price hit a new 52-week low during mid-day trading on Tuesday. The company traded as low as GBX 4.50 and last traded at GBX 5, with a volume of 288,979 shares trading hands. The stock had previously closed at GBX 4.75.
Allergy Therapeutics Stock Down 2.7%
The company has a debt-to-equity ratio of 629.58, a current ratio of 1.13 and a quick ratio of 1.48. The stock has a 50 day simple moving average of GBX 5.13 and a 200-day simple moving average of GBX 7.32. The firm has a market cap of £292.56 million, a PE ratio of -4.76, a PEG ratio of -30.70 and a beta of 0.83.
About Allergy Therapeutics
Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development.
Further Reading
- Five stocks we like better than Allergy Therapeutics
- Big Banks Report Strong Earnings—So Why Are Shares Falling?
- Mortgage Rates Squeeze FHA Buyers: 3 Housing Stocks to Watch
- UnitedHealth Beats on Earnings, But Investors Question Growth Path
- Swarm Economics: Can XTEND AI Robotics Deliver at Scale?
Receive News & Ratings for Allergy Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergy Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
